Analyst Price Targets — CYTK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:30 am | Leonid Timashev | RBC Capital | $117.00 | $85.57 | TheFly | Cytokinetics price target lowered to $117 from $119 at RBC Capital |
| June 29, 2026 10:19 am | Ashwani Verma | UBS | $115.00 | $82.19 | TheFly | Cytokinetics upgraded to Buy from Neutral at UBS |
| June 24, 2026 11:01 am | — | Mizuho Securities | $118.00 | $80.01 | TheFly | Cytokinetics price target raised to $118 from $100 at Mizuho |
| June 17, 2026 11:34 am | Leonid Timashev | RBC Capital | $119.00 | $75.21 | StreetInsider | RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move' |
| May 11, 2026 10:17 am | — | H.C. Wainwright | $140.00 | $76.91 | TheFly | Cytokinetics price target raised to $140 from $136 at H.C. Wainwright |
| May 6, 2026 1:15 pm | — | Morgan Stanley | $103.00 | $73.82 | TheFly | Cytokinetics price target raised to $103 from $90 at Morgan Stanley |
| May 6, 2026 12:51 pm | — | UBS | $119.00 | $74.34 | TheFly | Cytokinetics price target raised to $119 from $101 at RBC Capital |
| May 6, 2026 11:17 am | — | Stifel Nicolaus | $108.00 | $77.09 | TheFly | Cytokinetics price target raised to $108 from $98 at Stifel |
| May 5, 2026 2:26 pm | Srikripa Devarakonda | Truist Financial | $106.00 | $76.59 | TheFly | Cytokinetics price target raised to $106 from $92 at Truist |
| April 10, 2026 12:01 pm | — | Wells Fargo | $95.00 | $64.66 | TheFly | Cytokinetics initiated with an Overweight at Wells Fargo |
Latest News for CYTK
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement…
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity holdings.
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CYTK.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.